XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jun. 30, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Aug. 30, 2019
Oct. 31, 2018
Apr. 30, 2018
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2020
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenues                   $ 114,943 $ 199,074    
Grant funding liability                   $ 4,121,989     $ 2,475,031
Advaccine | Collaborative Arrangement, Product                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront payment received   $ 3,000,000                 1,200,000    
Additional revenue to be achieved   200,000,000                      
Royalty period                   10 years      
Annual maintenance fee                   $ 1,500,000      
Annual maintenance period                   5 years      
Agreement, number of days written notice before termination                   18 months      
Collaboration agreement, payment earned   $ 2,000,000                      
Revenues                       $ 5,000,000  
Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements, including from affiliated entities                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenues                   $ 0      
ApolloBio | Collaborative Arrangement, Product                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Additional revenue to be achieved                   $ 20,000,000      
Royalty period                   10 years      
Agreement, number of days written notice before termination                   90 days      
Period from effective date for termination                   1 year      
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Collaborative agreement, funding to be received       $ 6,900,000                  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Deferred grant funding, from affiliate                   $ 1,700,000      
Collaborative agreement, funding to be received                 $ 56,000,000        
Collaborative agreement, period to receive funding for research and development                 5 years        
Funding received for research and development                   1,600,000 2,000,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Collaborative agreement, funding to be received       5,000,000                  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Collaborative agreement, funding to be received       $ 1,300,000   $ 9,000,000              
Funding received for research and development                   53,000 510,000    
Grant funding liability                   2,300,000      
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Funding received for research and development         $ 5,000,000         0 0    
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Funding received for research and development             $ 1,100,000 $ 2,200,000   59,000 80,000    
Grant funding liability                   96,000      
Department of Defence | Collaborative Arrangement, Product                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contra-research and development expense                   0 3,200,000    
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Funding received for research and development     $ 54,500,000                    
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Purchase price, procurement contract $ 10,700,000   $ 16,800,000                    
Collaborative arrangement , revenue from the procurement contract                   $ 0 $ 0